CON: "Lifetime use" is an awfully long time

American Journal of Gastroenterology

Volumn 100, Issue 7, 2005, Pages 1435-1438

  Loftus Jr , Edward V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO; GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

CLINICAL TRIAL; CORTICOSTEROID THERAPY; CROHN DISEASE; DEATH; DRUG COST; DRUG SAFETY; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; LONG TERM CARE; MAINTENANCE THERAPY; MEDICARE; META ANALYSIS; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REMISSION; RISK REDUCTION; SHORT COURSE THERAPY; SHORT SURVEY; SYSTEMATIC REVIEW; DRUG ADMINISTRATION; ECONOMICS; EVALUATION; REVIEW;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 22744449734     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.50622_2.x     Document Type: Short Survey

References (15)

1. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53.
2. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9.
4. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
5. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13.
6. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial. Gastroenterology 2003;124:917-24.
7. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002;123:707-13.
8. Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002;97:2357-63.
9. Lemann M, Colombel JF, Duclos B, et al. Infliximab in steroid-dependent Crohn's disease patients treated with azathioprine or 6-mercaptopurine: A randomized double-blind placebo-controlled trial [Abstract]. Gastroenterology 2003;125:606.
10. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593-610.
11. Wong JB, Loftus EV, Sandborn WJ, et al. Estimating cost-effectiveness of maintenance infliximab for chronic active Crohn's disease from ACCENT I [Abstract]. Gut 2003;52:A54.
12. Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 2004;53:780-2.
13. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: Clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53.
14. Colombel JF, Loftus EV Jr., Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
15. Lichtenstein GR, Cohen RD, Feagan BG, et al. Safety of infliximab in Crohn's disease: Data from the 5000 patient TREAT registry [Abstract]. Gastroenterology 2004;126:A.